Improving the Treatment Gap in Diffuse Large B-Cell Lymphoma
Gilles Salles, MD, discusses the need for new therapies to treat diffuse large B-cell lymphoma.
Gilles Salles, MD, the lymphoma service chief at Memorial Sloan Kettering Cancer Center, discusses the need for new therapies to treat diffuse large B-cell lymphoma (DLBCL).
According to Salles, once patients fail primary therapy, limited options remain. For approximately 50% of the patient population, those with limited comorbidities or those under a certain age, the standard of care is salvage chemotherapy followed by stem cell transplant.
However, for the approximately half of patients who are not eligible for this route, the treatment is usually immuno-chemotherapy, according to Salles. For most regimens, the response rate is limited. For patients who do respond, the duration of response (DOR) is typically only between 4 to 6 months. The median survival after the second-line therapy is about a year.
News agents have made progress in this space. For example, chimeric antigen receptor T cells show promise, but eligibility and access remain a major hurdle for many patients. New agents are also in the pipeline, though according to Salles, many have a short DOR.
Lunning Evaluates CAR T-Cell Therapy for ASCT-Eligible and Ineligible DLBCL
September 22nd 2024During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen receptor T-cell therapies in patients with diffuse large B-cell lymphoma.
Read More
Saeed Discusses Long-Term Outcomes and Real-World Data for Tafasitamab/ Lenalidomide in R/R DLBCL
August 15th 2024During an in-person Community Case Forum event, Hayder Saeed, MD, discussed the RE-MIND2 matched cohort data and real-world data on the combination of tafasitamab and lenalidomide in patients with diffuse large B-cell lymphoma.
Read More
Takeaways on Tolerability Challenges With Loncastuximab in DLBCL
July 30th 2024During a Case-Based Roundtable® event, Amitkumar Mehta, MD, discussed the study design of the LOTIS-2 trial and adverse events related to loncastuximab tesirine in diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Glofitamab/Chemo Leads to Survival Benefit in Transplant-Ineligible R/R DLBCL
July 3rd 2024A study found that glofitamab plus gemcitabine and oxaliplatin significantly improved survival in patients with relapsed/refractory diffuse large B-cell lymphoma who were not eligible for stem cell transplant.
Read More
